🚀 VC round data is live in beta, check it out!
Pharmena Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pharmena and similar public comparables like Aqua Bio Technology, Mycodern, BioRegenx, Arctic Bioscience and more.
Pharmena Overview
About Pharmena
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
Founded
2002
HQ
Employees
20
Website
Financials (FY)
EV
$9M
Pharmena Financials
Pharmena reported last fiscal year revenue of $439K and negative EBITDA of ($724K).
In the same fiscal year, Pharmena generated $366K in gross profit, ($724K) in EBITDA losses, and had net loss of ($771K).
Pharmena P&L
In the most recent fiscal year, Pharmena reported revenue of $439K and EBITDA of ($724K).
Pharmena expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $439K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $366K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 83% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($724K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (165%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (207%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($771K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (176%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pharmena Stock Performance
Pharmena has current market cap of $11M, and enterprise value of $9M.
Market Cap Evolution
Pharmena's stock price is $0.97.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9M | $11M | 0.1% | XXX | XXX | XXX | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPharmena Valuation Multiples
Pharmena trades at 20.1x EV/Revenue multiple, and (12.2x) EV/EBITDA.
Pharmena Financial Valuation Multiples
As of April 19, 2026, Pharmena has market cap of $11M and EV of $9M.
Equity research analysts estimate Pharmena's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pharmena has a P/E ratio of (14.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV (current) | $9M | XXX | $9M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 20.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (12.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (9.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 24.1x | XXX | XXX | XXX |
| P/E | — | XXX | (14.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pharmena Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pharmena Margins & Growth Rates
Pharmena's revenue in the last fiscal year grew by 488%.
Pharmena's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.
Pharmena Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 488% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (165%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 7% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 139% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 152% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 291% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pharmena Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pharmena | XXX | XXX | XXX | XXX | XXX | XXX |
| Aqua Bio Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Mycodern | XXX | XXX | XXX | XXX | XXX | XXX |
| BioRegenx | XXX | XXX | XXX | XXX | XXX | XXX |
| Arctic Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Simris Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharmena M&A Activity
Pharmena acquired XXX companies to date.
Last acquisition by Pharmena was on XXXXXXXX, XXXXX. Pharmena acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pharmena
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPharmena Investment Activity
Pharmena invested in XXX companies to date.
Pharmena made its latest investment on XXXXXXXX, XXXXX. Pharmena invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pharmena
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pharmena
| When was Pharmena founded? | Pharmena was founded in 2002. |
| Where is Pharmena headquartered? | Pharmena is headquartered in Poland. |
| How many employees does Pharmena have? | As of today, Pharmena has over 20 employees. |
| Is Pharmena publicly listed? | Yes, Pharmena is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Pharmena? | Pharmena trades under PHR ticker. |
| When did Pharmena go public? | Pharmena went public in 2008. |
| Who are competitors of Pharmena? | Pharmena main competitors are Aqua Bio Technology, Mycodern, BioRegenx, Arctic Bioscience. |
| What is the current market cap of Pharmena? | Pharmena's current market cap is $11M. |
| What is the current revenue of Pharmena? | Pharmena's last fiscal year revenue is $439K. |
| What is the current EV/Revenue multiple of Pharmena? | Current revenue multiple of Pharmena is 20.1x. |
| Is Pharmena profitable? | No, Pharmena is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.